Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BHARAT BIOTECH INTERNATIONAL LIMITED currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, indicating a diverse range of individual reviewers for the company's filings. Despite the involvement of multiple examiners, the pending actions are contained within 1 distinct art unit, suggesting a high degree of technical specialization in the portfolio's current focus. This concentration within a single art unit implies that the patent office has assigned these matters to a specific technical group despite the varied examiner assignments.
MICHAEL D ALLEN is the busiest examiner for the portfolio, currently handling 1 busiest examiner pending office action. With 3 pending office actions and 3 distinct examiners, the workload is distributed across several individuals within the art unit. This requires the company to navigate different examiner preferences while remaining within the same administrative technical group. For the practitioner, this necessitates a strategy that accounts for the specific tendencies of the examiners while addressing the common standards of the art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| LI, BAO Q | 1 | 75.4% | +26.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026404 | NOVEL AGONIST VACCINE FORMULATION | LI, BAO Q | 34d |
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | — |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026404 | NOVEL AGONIST VACCINE FORMULATION | LI, BAO Q | 34d |
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | — |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294775 | SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTERAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19 | ALLEN, MICHAEL D | 1671 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18565210 | ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS | ZOU, NIANXIANG | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18026404 | NOVEL AGONIST VACCINE FORMULATION | LI, BAO Q | 1671 | §103§112 | Non-Final OA | 34d | Pending | Mar 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial